AZD1152 in Patients With Advanced Solid Malignancies

This study is ongoing, but not recruiting participants.

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00338182

Purpose

The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 48-hour infusion every 14 days and as a 2-hour infusion for 2 consecutive days every 14 days in patients with advanced solid malignancies.

Condition	Intervention	Phase
Tumors	Drug: AZD1152	Phase I

MedlinePlus related topics: Cancer

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacokinetics Study
Official Title:	A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 48-Hour Intravenous Infusion in Patients With Advanced Solid Malignancies

Further study details as provided by AstraZeneca:

Estimated Enrollment:	70
Study Start Date:	May 2006
Estimated Study Completion Date:	September 2008

Intervention Details:

48-hour continuous intravenous infusion

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Histological or cytological confirmation of a solid, malignant tumour
At least one measurable or non-measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

Exclusion Criteria:

Participation in an investigational drug study within the 21 days prior to therapy or those who have not recovered from the effects of an investigational study drug
Recent major surgery within 4 weeks prior to entry into the study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00338182

Locations

United States, Massachusetts
Research Site
Boston, Massachusetts, United States
United States, New York
Research Site
New York, New York, United States

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

Emerging Oncology Medical Science Director, MD

AstraZeneca

More Information

Study ID Numbers:	D1531C00002
Study First Received:	June 16, 2006
Last Updated:	April 16, 2008
ClinicalTrials.gov Identifier:	NCT00338182
Health Authority:	United States: Food and Drug Administration

Keywords provided by AstraZeneca:

Solid tumor

ClinicalTrials.gov processed this record on January 14, 2009